Mainz Biomed Partners with Trusted Health Advisors to Support U.S. Go-To-Market Strategy for Next Generation Early Colorectal Cancer Diagnostic  Dr. Jay Wohlgemuth, former Chief Medical & Scientific Officer of Quest Diagnostics and Dr. Ray Tabibiazar, a seasoned industry executive, to lead collaboration   Mainz Biomed’s Pivotal FDA PMA clini [ … ]

Mainz Biomed to Showcase at the Gynecology Conference in Stuttgart, Germany, Strengthening Connections within the Medical Community BERKELEY, US – MAINZ, Germany – February 27th 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, is proud to annou [ … ]

Mainz Biomed Announces Distribution Partnership with Praxisdienst for ColoAlert® BERKELEY, US – MAINZ, Germany – February 22nd, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, is pleased to announce a distribution partnership with Praxisdienst [ … ]

Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy Partnership Brings Pioneering Approach to Incorporating Advanced Colorectal Cancer Detection Into Country’s Healthcare System BERKELEY, US – MAINZ, Germany – February 21st, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Compan [ … ]

MAINZ BIOMED ESTABLISHES PHYSICIAN-LED LABORATORY EXPANDING SERVICE OFFERING FOR PRIVATELY INSURED PATIENTS IN GERMANY  Company opens own physician-led laboratory, ‘European Oncology Lab’ (EOL), thereby offering ColoAlert® as a laboratory medical service directly to physicians and patients. BERKELEY, US – MAINZ, Germany – February 6, 2024 — Mainz [ … ]

Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium BERKELEY, US – MAINZ, Germany – January 11, 2024 — Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in early cancer detection, re-affirms its collaboration with TestDNA at the upcoming 1 [ … ]

Mainz Biomed Provides Year-End Corporate Review 2023 European Study ColoFuture and U.S. Study eAArly DETECT report sensitivity and specificity for the detection of Colorectal Cancer and Advanced Adenoma exceeding competition   ReconAAsense designed to evaluate gold standard at home colorectal cancer screening test and is on track to commence enr [ … ]